list of investigational attention deficit hyperactivity disorder drugs list of investigational attention deficit hyperactivity disorder drugs this is a list of investigational attention deficit hyperactivity disorder drugs, or drugs that are currently under development for clinical use in the treatment of attention deficit hyperactivity disorder (adhd) but are not yet approved. chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. under development preregistration trn-110 - undefined mechanism / extended-release form of an undisclosed drug phase 3 clinical trials centanafadine (centanafadine sr, ctn-sr, eb-1020, eb-1020 sr) - serotonin–norepinephrine–dopamine reuptake inhibitor molindone (afx-2201, en-1733a, molindone xr, spn-810, spn-810m, zalvari) - antipsychotic / dopamine d2 receptor antagonist and serotonin receptor modulator (e.g., serotonin 5-ht2b and 5-ht2a receptor antagonist) - specifically under development for impulsive aggression in adhd serdexmethylphenidate (kp-484) - dexmethylphenidate prodrug / norepinephrine–dopamine reuptake inhibitor phase 2/3 clinical trials edivoxetine (ly-2216684) - norepinephrine reuptake inhibitor phase 2 clinical trials cx-717 - ampakine / ampa receptor modulator mazindol (nls-0, nls-1, nls-10, nls-13, nls-2, nolazol, quilience) - serotonin–norepinephrine–dopamine reuptake inhibitor pdc-1421 (bli-1005) - norepinephrine reuptake inhibitor phase 1/2 clinical trials dexmethylphenidate (ctx-1301) - norepinephrine–dopamine reuptake inhibitor phase 1 clinical trials afx-2401 - "neurotransmitter modulator" atomoxetine (tah-9922) - norepinephrine reuptake inhibitor brilaroxazine (rp-5000, rp-5063) - atypical antipsychotic / dopamine receptor partial agonist and serotonin receptor modulator dextroamphetamine (adair) - norepinephrine–dopamine releasing agent phacetoperane (nls-3) - methylphenidate analogue / central nervous system stimulant / norepinephrine–dopamine reuptake inhibitor (?) preclinical/research atomoxetine - norepinephrine reuptake inhibitor dextroamphetamine (ctx-1302) - norepinephrine–dopamine releasing agent methylphenidate (col-171) - norepinephrine–dopamine reuptake inhibitor methylphenidate/naltrexone (avk-001) - norepinephrine–dopamine reuptake inhibitor and opioid receptor antagonist nls-8 - undefined mechanism nni-351 - dyrk1a inhibitor and "neurogenesis enhancer" shx-009 - norepinephrine–dopamine reuptake inhibitor no development reported afi-002 - undefined mechanism altropane (123-i altropane®, -e-iacft injection, nav5001, cft, iodine-123-e-iacft injection, nav-5001, o-587) - dopamine reuptake inhibitor / single-photon emission-computed tomography enhancer amphetamine (adair) - norepinephrine–dopamine releasing agent bavisant (ben-2001, jnj-1074, jnj-31001074) - histamine h3 receptor antagonist bcwp-e003 - undefined mechanism bli-1008 - undefined mechanism cannabidiol/gabapentin (cannbleph) - cannabinoid receptor modulator and gabapentinoid ciforadenant (cpi-444, v-81444) - adenosine a2a receptor antagonist cm-4612 (cm-adhd, cm-at, cm-pk) - gastrointestinal/pancreatic enzyme replacement therapy crd-102 - undefined mechanism dasotraline (dsp-225289, sep-225289, sep-0225289, sep-225289-hci, sep-289) - serotonin–norepinephrine–dopamine reuptake inhibitor dextroamphetamine (pf-08, pfr 08001, pfr08026) – norepinephrine–dopamine releasing agent dextroamphetamine sulfate (hld-900, hld-100) - norepinephrine–dopamine releasing agent dopamine (dopamat, mpp-18) - dopamine receptor agonist eltoprazine (du-28853) - serotonin 5-ht1a and 5-ht1b receptor agonist fasoracetam (aevi-004, nfc-1) - racetam / metabotropic glutamate receptor modulator gts-21 (dmxb-a, dmxb-a sustained release, dmxb-a-sr) - α7 nicotinic acetylcholine receptor agonist guanfacine (guanfacine carrier wave, spd-547) - α2-adrenergic receptor agonist ipx-233 (ipx233 er c0003, ipx233-c0001, ipx233-c0002, ipx233-t0001, ipx233-t0002) - central nervous system stimulant masupirdine (m1, m1 of suvn-502, suvn-502, svn-502) - serotonin 5-ht6 receptor antagonist methylphenidate - norepinephrine–dopamine reuptake inhibitor nic-12 - undefined mechanism nls-2 - antianaemic / heavy metal / iron replacement pd-3044 - dopamine reuptake inhibitor pitolisant (tiprolisant; bf-2.649, bf-2649, ozawade, wakix) - histamine h3 receptor antagonist r-sibutramine metabolite ((+)-desmethylsibutramine, (+)-didesmethylsibutramine, r-ddms, r-desmethylsibutramine, r-didesmethylsibutramine) - serotonin–norepinephrine–dopamine reuptake inhibitor selegiline (emsam) - monoamine oxidase b inhibitor skl-13865 (skl-adhd) - norepinephrine–dopamine reuptake inhibitor sofinicline (a-422894.0, abt-894) - α4β2 nicotinic acetylcholine receptor modulator spn-811 - undefined mechanism taminadenant (nir-178, pbf-509) - adenosine a2a receptor antagonist research programmes ampakines / ampa receptor modulators (cx-516, cx-614, cx-707, cx-929, cx-1501, cx-1763, cx-1796, cx-1837, cx-1846, cx-1942, cx-2007, cx-2076) cannabis extracts (cbis gap-001, cbis lc-001, cbis obld-001, cbis ocd-001, cbis pc-001, cbis ppc-001, cbis ps-001, cbis sd-001, cbis ssa-001, cbis-os-001, cbis-ptsd-001, cs neuro 1, cs-s/bcc-1, cs-tati-1) - cannabinoid receptor modulators norepinephrine reuptake inhibitors / adrenergic receptor antagonists (nri-022, nri-193, way-253203, way-256805, way-260022, way-315193, way-318068) pim2 / polyphetamine subtype-selective glutamate nmda receptor modulators / glutamate nr2b receptor modulators not under development development discontinued abt-418 - nicotinic acetylcholine receptor agonist amphetamine - norepinephrine–dopamine releasing agent ampreloxetine (td-9855) - norepinephrine reuptake inhibitor ar-08 - adrenergic receptor agonist aripiprazole (abilify, abilify maintena, abilify mycite, abilitat, ao pai, aripiprazole depot, aripiprazole ecer tablets, arlemide; opc-14597, opc-14597 imd, opc-31) - atypical antipsychotic / dopamine receptor partial agonist and serotonin receptor modulator azd-5213 - histamine h3 receptor antagonist bifemelane (son-216) - monoamine oxidase inhibitor and weak norepinephrine reuptake inhibitor bradanicline (ata-101, tc-0569, tc-5619, tc-5619-238) - α7 nicotinic acetylcholine receptor agonist brexpiprazole (rexulti, rxulti; lu-af41156, opc-34712, opdc-34712) - atypical antipsychotic / dopamine receptor partial agonist and serotonin receptor modulator buspirone (buspar patch) - serotonin 5-ht1a receptor partial agonist, other actions cipralisant (gt-2331; perceptin) - histamine h3 receptor antagonist cx-516 (1-bcp, ampalex, bdp-12, spd-420) - ampakine / ampa receptor modulator cx-1739 - ampakine / ampa receptor modulator donepezil (aricept, aricept d, aricept dry syrup, aricept evess, aricept odt, aricept sr, donepezil sr, e-2020, e-2022, eranz) - acetylcholinesterase inhibitor droxidopa (3,4-dihydroxyphenylserine, 3,4-threo-dops, l-threo-dihydroxyphenylserine, l-threodops, northera, threo-dopaserine, threo-dops) - prodrug of norepinephrine / adrenergic receptor agonist fasoracetam (aevi-001, lam-105, mdgn-001, nfc-1, ns-105) - racetam / metabotropic glutamate receptor modulator ispronicline (azd-3480, rjr-1734, tc 01734, tc-1734, tc-1734-112) - α4β2-nicotinic acetylcholine receptor agonist kp-106 (dextroamphetamine prodrug oral film) - norepinephrine–dopamine releasing agent lauflumide (flmodafinil, bisfluoromodafinil; nls-14, nls-4) - weak dopamine reuptake inhibitor, possibly other actions manifaxine (bw-1555u88, gw-320659) - norepinephrine–dopamine reuptake inhibitor mecamylamine (inversine, tridmac) - nicotinic acetylcholine receptor antagonist mem-68626 - 5-ht6 receptor antagonist metadoxine (pyridoxine-pyrrolidone carboxylate, pyridoxine pidolate; mdx, metadoxine sr, mg-01ci) - serotonin 5-ht2b receptor antagonist, gaba modulator, other actions methylphenidate (tah-9901) - norepinephrine–dopamine reuptake inhibitor mk-0249 - histamine h3 receptor antagonist modafinil (aft-801, alertec, attenace, cn-801, crl-40476, modasamil, modasonil, modavigil, modiodal, provigil, sparlon, vigil) - weak dopamine reuptake inhibitor, possibly other actions nicotine/opipramol (nd-0801; opipramol/nicotine) - tricyclic antidepressant / monoamine and sigma receptor modulator and nicotinic acetylcholine receptor agonist ns-2359 (gsk-372475) - serotonin–norepinephrine–dopamine reuptake inhibitor opc-64005 - serotonin–norepinephrine–dopamine reuptake inhibitor org-26576 (org26576) - ampakine / ampa receptor modulator pf-3654746 (pf-03654746) - histamine h3 receptor antagonist pirepemat (irl-752) - "cortical enhancer" / serotonin 5-ht7 receptor antagonist and α2c-adrenergic receptor antagonist, other actions pozanicline (a-87089.0, abt-089) - α4β2 nicotinic acetylcholine receptor agonist sep-225432 - serotonin–norepinephrine–dopamine reuptake inhibitor sgs-742 (cgp-36742, dvd-742, lu-ae58479, sgs-742) - gabab receptor antagonist spd-483 - undefined mechanism spd-554 (guanfacine carrier wave project) - α2-adrenergic receptor agonist spi-339 (neo-339) - undefined mechanism tak-137 - ampa receptor potentiator tc-6683 (azd 1446, tc-6683) - α4β2 nicotinic acetylcholine receptor agonist tipepidine (ts-141) - girk inhibitor vortioxetine (brintellix, lu-aa21004, luaa 21004, trintellix) - antidepressant / serotonin reuptake inhibitor and serotonin receptor modulator research programmes potassium channel modulators formal development never or not yet started dopamine precursors (l-phenylalanine, l-tyrosine, l-dopa (levodopa)) clinically used drugs norepinephrine–dopamine releasing agents amphetamine (adzenys er, adzenys xr-odt, dyanavel xr, evekeo, evekeo odt) dextroamphetamine (dexedrine, zenzedi, xelstrym) fenethylline (biocapton, captagon, fitton) - amphetamine and theophylline prodrug - discontinued/no longer used lisdexamfetamine (elvanse, tyvense, venvanse, vyvanse) - dextroamphetamine prodrug methamphetamine (dextromethamphetamine; desoxyn, methampex) mixed amphetamine salts (adderall, adderall ir, adderall xr, mydayis) pemoline (betanamin, ceractiv, cylert, tradon) - withdrawn/discontinued due to toxicity norepinephrine–dopamine reuptake inhibitors dexmethylphenidate (focalin, focalin xr) methylphenidate (adhansia xr, aptensio xr, benjorna, biphentin, concerta, cotempla xr-odt, daytrana, equasym, foquest, jornay pm, metadate, metadate cd, metadate er, methydur, methypatch, oradur, quillichew er, quillivant xr, ritalin, ritalin sr) serdexmethylphenidate/dexmethylphenidate (azstarys) norepinephrine reuptake inhibitors atomoxetine (tomoxetine; strattera) viloxazine (qelbree) α2-adrenergic receptor agonists clonidine (catapres, clonibid, clonicel, jenloga xr, kapvay) guanfacine (connexyn, intuniv, intuniv xr, tenex) off-label drugs bupropion (wellbutrin) - norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist modafinil (provigil) - weak dopamine reuptake inhibitor, possibly other actions reboxetine (edronax) - norepinephrine reuptake inhibitor serotonin–norepinephrine reuptake inhibitors (e.g., venlafaxine (effexor), duloxetine (cymbalta)) tricyclic antidepressants (e.g., desipramine (norpramin) – norepinephrine reuptake inhibitor)